Clinical Study
Echocardiographic Findings and Their Impact on Outcomes of Critically Ill Patients with AIDS in the Era of HAART
Table 1
Demographics, length of stay, and mortality.
| | Age, yrs. mean ± SD | | | Sex | | | Male, number (%) | 44 (70) | | Female, number (%) | 18 (29) | | Race | | | Black, number (%) | 56 (90) | | Caucasian, number (%) | 6 (10) | | HAART therapy | | | Yes | 19 (31) | | No | 43 (70) | | CD4 count, | | | HIV viral load, copies/mL. | | | APACHE II score, | | | APACHE II predicted mortality, | | | ICU LOS, median (IQR 25–75) | 3 (2–7) | | Hospital LOS, median (IQR 25–75) | 10 (5–19) | | Ventilator days, median (IQR 25–75) | 3 (2–7) | | ICU mortality, number (%) | 21 (33) | | Hospital mortality, number (%) | 21 (33) |
|
|
LOS: length of stay; HAART: highly active antiretroviral therapy.
|
